Header Logo

Connection

Mary Jo Fidler to Female

Back to Details
This is a "connection" page, showing publications Mary Jo Fidler has written about Female.
Mary Jo Fidler
Connection Strength
0.580
Female
  1. The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
    View in: PubMed
    Score: 0.048
  2. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Cancer. 2014 Jul 01; 120(13):2060-8.
    View in: PubMed
    Score: 0.037
  3. Prevalence and predictors of neoadjuvant therapy for stage IIIA non-small cell lung cancer in the National Cancer Database: importance of socioeconomic status and treating institution. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):303-12.
    View in: PubMed
    Score: 0.037
  4. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
    View in: PubMed
    Score: 0.032
  5. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
    View in: PubMed
    Score: 0.031
  6. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94.
    View in: PubMed
    Score: 0.024
  7. Unusual vasovagal-type autonomic dysfunction secondary to immune checkpoint inhibitor therapy. BMJ Case Rep. 2023 Feb 20; 16(2).
    View in: PubMed
    Score: 0.017
  8. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
    View in: PubMed
    Score: 0.016
  9. In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. J Am Soc Nephrol. 2021 03; 32(3):695-706.
    View in: PubMed
    Score: 0.015
  10. De novo pauci-immune glomerulonephritis in renal allografts. Mod Pathol. 2020 03; 33(3):440-447.
    View in: PubMed
    Score: 0.013
  11. The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry. Kidney Int. 2019 10; 96(4):1005-1009.
    View in: PubMed
    Score: 0.013
  12. Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer. Am J Otolaryngol. 2019 Sep - Oct; 40(5):626-630.
    View in: PubMed
    Score: 0.013
  13. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. J Thorac Oncol. 2019 05; 14(5):793-801.
    View in: PubMed
    Score: 0.013
  14. Clinical features and outcomes in young adults with oral tongue cancer. Am J Otolaryngol. 2019 Jan - Feb; 40(1):93-96.
    View in: PubMed
    Score: 0.013
  15. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2018 09; 13(9):1393-1399.
    View in: PubMed
    Score: 0.012
  16. Congophilic Fibrillary Glomerulonephritis: A Case Series. Am J Kidney Dis. 2018 09; 72(3):325-336.
    View in: PubMed
    Score: 0.012
  17. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney Int. 2018 07; 94(1):159-169.
    View in: PubMed
    Score: 0.012
  18. National patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma. Cancer. 2017 01 01; 123(2):273-282.
    View in: PubMed
    Score: 0.011
  19. Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis. Oral Oncol. 2016 Mar; 54:58-67.
    View in: PubMed
    Score: 0.010
  20. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 09; 387(10027):1540-1550.
    View in: PubMed
    Score: 0.010
  21. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
    View in: PubMed
    Score: 0.010
  22. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.010
  23. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int. 2015 Oct; 88(4):867-73.
    View in: PubMed
    Score: 0.010
  24. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):307-16.
    View in: PubMed
    Score: 0.010
  25. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer. 2015 Jun; 88(3):267-74.
    View in: PubMed
    Score: 0.010
  26. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80.
    View in: PubMed
    Score: 0.010
  27. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. J Clin Oncol. 2015 Jan 10; 33(2):189-94.
    View in: PubMed
    Score: 0.010
  28. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int. 2015 Feb; 87(2):458-64.
    View in: PubMed
    Score: 0.009
  29. Biopsy-proven acute interstitial nephritis, 1993-2011: a?case?series. Am J Kidney Dis. 2014 Oct; 64(4):558-66.
    View in: PubMed
    Score: 0.009
  30. Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: implications for CTV margin, elective nodal dose and bilateral parotid sparing. Oral Oncol. 2014 May; 50(5):520-6.
    View in: PubMed
    Score: 0.009
  31. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014 Aug; 86(2):370-7.
    View in: PubMed
    Score: 0.009
  32. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
    View in: PubMed
    Score: 0.009
  33. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.008
  34. Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol Dial Transplant. 2012 Nov; 27(11):4137-46.
    View in: PubMed
    Score: 0.008
  35. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012 Jun; 59(6):786-94.
    View in: PubMed
    Score: 0.008
  36. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012 Feb; 7(2):231-9.
    View in: PubMed
    Score: 0.008
  37. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2012 Mar; 27(3):1097-101.
    View in: PubMed
    Score: 0.008
  38. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011 Oct; 80(7):753-9.
    View in: PubMed
    Score: 0.008
  39. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.007
  40. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
    View in: PubMed
    Score: 0.007
  41. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.007
  42. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation. 2005 Dec 15; 80(11):1572-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.